Insider Selling: KALA BIO, Inc. (NASDAQ:KALA) Insider Sells $15,420.23 in Stock

KALA BIO, Inc. (NASDAQ:KALA) insider Darius Kharabi sold 2,021 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.63, for a total value of $15,420.23. Following the transaction, the insider now directly owns 67,807 shares of the company’s stock, valued at approximately $517,367.41. The trade was a 2.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

KALA BIO Stock Down 11.3 %

Shares of KALA opened at $6.82 on Friday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. KALA BIO, Inc. has a 52 week low of $4.21 and a 52 week high of $9.25. The stock has a market capitalization of $31.44 million, a price-to-earnings ratio of -0.55 and a beta of -2.11. The stock has a fifty day moving average of $6.70 and a 200-day moving average of $6.33.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. As a group, sell-side analysts anticipate that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On KALA BIO

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO accounts for 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest holding. SR One Capital Management LP owned 15.76% of KALA BIO as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of KALA BIO in a report on Friday, November 15th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.